Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneWith the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility Paris, July 25, 2025. Following the positive opinion by the European Medi ...

Core Viewpoint - Sanofi has successfully completed the acquisition of Blueprint Medicines, enhancing its portfolio with a commercialized medicine and a promising pipeline focused on systemic mastocytosis and other KIT-driven diseases [1][6]. Group 1: Acquisition Details - The acquisition includes Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis in the US and EU [3][10]. - Sanofi also acquired elenestinib, a next-generation investigational medicine for systemic mastocytosis, currently undergoing a phase 2/3 clinical study [4]. - Additionally, BLU-808, an investigational oral KIT inhibitor, was part of the acquisition, targeting a range of inflammatory diseases [5]. Group 2: Financial Aspects - The tender offer for Blueprint's shares was completed on July 17, 2025, with all conditions satisfied [6]. - Sanofi financed the acquisition through cash on hand and proceeds from commercial paper issuances, indicating it will not significantly impact the company's financial guidance for 2025 [7]. - The acquisition is expected to be immediately accretive to gross margin and business operating income, as well as EPS after 2026 [7]. Group 3: Market Impact - Following the acquisition, Blueprint common stock will cease trading on the NASDAQ Global Select Stock Market as of July 18, 2025 [9]. - All shares not validly tendered will convert to a cash payment of $129.00 per share, plus potential contingent payments of up to $6.00 per share based on milestone achievements [8].

Mergers and Acquisitions - Goldman Sachs 同意从 Santander 银行购买约 460 million 欧元（约合 5 亿美元）的西班牙抵押贷款 [1]

Core Points - Sanofi has extended its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation at a price of $129.00 per share in cash, plus contingent rights for additional payments of up to $6.00 per share based on specified milestones [1][2] - The expiration date for the tender offer has been moved to 17:00 EDST on July 17, 2025, from the previous date of July 16, 2025 [2] - As of July 16, 2025, approximately 29,742,419 shares, or 45.85% of Blueprint's total outstanding shares, have been validly tendered, with an additional 23,400,152 shares tendered by notice of guaranteed delivery, representing 36.08% of the outstanding shares [3] Offer Details - The tender offer is subject to conditions outlined in the offer to purchase, including the requirement for a majority of Blueprint's outstanding shares to be tendered [5] - The offer is being managed by Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, and Innisfree M&A Incorporated is acting as the information agent for the offer [4][6] Company Background - Sanofi is a research and development-driven biopharmaceutical company focused on improving lives through innovative medicines and vaccines, leveraging its understanding of the immune system [7]

Core Insights - The FDA has granted fast track designation to Sanofi's SAR446597, a one-time intravitreal gene therapy for geographic atrophy due to age-related macular degeneration [1][2] - This designation aims to expedite the development and review of treatments for serious conditions, addressing unmet medical needs [1] Product Details - SAR446597 delivers genetic material encoding two therapeutic antibody fragments that inhibit critical components of the complement pathway, potentially offering sustained complement suppression and reducing treatment burden [2] - The therapy targets the underlying pathophysiology of complement-mediated retinal diseases through long-term expression of therapeutic proteins after a single intervention [2] Clinical Development - Sanofi plans to initiate a phase 1/2 study to evaluate the safety, tolerability, and efficacy of SAR446597 [3] - Additionally, Sanofi is evaluating another gene therapy, SAR402663, for neovascular wet age-related macular degeneration in a phase 1/2 study [3] Market Context - Age-related macular degeneration (AMD) affects approximately 200 million people globally, with geographic atrophy being a severe form that can lead to permanent vision loss [4] - Geographic atrophy impacts around 1 million people in the US, over 2.5 million in Europe, and more than 5 million worldwide, significantly affecting quality of life [4] Company Focus - Sanofi aims to improve the lives of individuals with serious neuroinflammatory and neurodegenerative diseases, including AMD, through innovative therapies [5] - The company is leveraging scientific innovations and investments in ophthalmology to drive growth and address unmet needs in retinal diseases [5][6]

Market Sentiment - Banco Santander Executive Chair Ana Botin expresses an optimistic view on Europe's economic prospects, contrasting with JPMorgan CEO Jamie Dimon's pessimistic outlook [1] Leadership Perspective - Ana Botin sees "only upside" for the European continent [1]

南方财经记者 黄子潇 深圳报道 近日，桑坦德银行正式获批筹建深圳分行，第三次落子中国内地。 此前，这家西班牙最大的银行已设立上海分行、北京分行，不过尚未在内地注册为法人银行，在展业上 受到一定限制。 过去，桑坦德银行选择与上海银行、北京银行等城商行合作，以开拓中国市场。 如今，其深圳分行获批后，业务定位如何、是否寻求当地银行的合作、如何切入深圳市场等，均是值得 探究的问题。 21世纪经济报道记者独家获悉，桑坦德银行深圳分行将延续前述本地化策略，利用母行的全球网络优势 服务境内企业出海，而与一家头部城商行深圳分行的合作将成为关键一环。 "双方经营区域高度重叠，但经营侧重仍各有不同，有着天然的互补性。"相关人士向21世纪经济报道记 者介绍。 延续城商行合作模式 非法人银行的业务范围受到限制。过去，桑坦德银行选择了与北京银行、上海银行合作，借助这些城商 行的本地网络切入中国市场。而记者独家了解到，这一做法也将在深圳延续。 服务湾区企业出海 去年12月，21世纪经济报道曾报道，西班牙桑坦德银行董事会已决策通过在深圳设立分行，为西语国家 公民和西语国家企业提供金融服务。同月，该行在深圳全球招商大会上与当地政府正式签约。 ...

Company Overview - Banco Santander (SAN) is based in Madrid and operates in the Finance sector, with shares experiencing a price change of 88.16% this year [3] - The company currently pays a dividend of $0.09 per share, resulting in a dividend yield of 2.11%, which is lower than the Banks - Foreign industry's yield of 3.33% and the S&P 500's yield of 1.52% [3] Dividend Performance - The current annualized dividend of Banco Santander is $0.18, reflecting a 20% increase from the previous year [4] - Over the past 5 years, the company has increased its dividend 4 times year-over-year, averaging an annual increase of 35.07% [4] - The current payout ratio is 18%, indicating that the company paid out 18% of its trailing 12-month earnings per share as dividends [4] Earnings Expectations - The Zacks Consensus Estimate for Banco Santander's earnings in 2025 is $0.97 per share, with an expected increase of 16.87% from the previous year [5] Investment Considerations - Income investors favor dividends for enhancing stock investing profits, reducing overall portfolio risk, and providing tax advantages [5] - High-growth firms or tech start-ups typically do not offer dividends, while larger, established companies are viewed as better dividend options [6] - Banco Santander is considered a compelling investment opportunity due to its strong dividend profile and current Zacks Rank of 3 (Hold) [6]

Core Points - The document provides information regarding the total number of voting rights and shares of Sanofi as of June 30, 2025 [1] - Sanofi has a registered share capital of €2,452,461,656 [1] Summary by Category Voting Rights and Shares - Total number of issued shares is 1,227,756,274 [1] - The number of real voting rights, excluding treasury shares, is 1,351,296,496 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,952,562 [1]

Group 1 - The core point of the news is the approval of Banco Santander to establish a branch in Shenzhen, marking its third presence in China after Shanghai and Beijing, and reflecting the ongoing expansion of foreign financial institutions in the region [1][4][10] - Banco Santander, as Spain's largest commercial bank, has a significant global presence with total assets of €1.8 trillion and annual revenue of €61.876 billion as of the end of 2024 [1][4] - The establishment of the Shenzhen branch aligns with China's financial opening policies, which have seen over 50 measures introduced since 2018 to facilitate foreign investment in the banking sector [4][9] Group 2 - Shenzhen has become a hub for foreign banks, with 38 institutions having total assets exceeding 400 billion RMB, ranking among the top in the country [5][6] - The historical context of foreign banks in Shenzhen dates back to 1982, with significant milestones including the establishment of the first foreign bank and the introduction of various international banking giants [5][6] - Recent developments indicate a trend of foreign banks increasing their presence in Shenzhen, supported by favorable policies and the city's strong economic performance [6][9] Group 3 - Foreign banks in Shenzhen are actively participating in cross-border financing and settlement, with significant contributions to the "Cross-Border Wealth Management Connect" pilot program [7] - These banks are also supporting Chinese enterprises in their global expansion efforts, leveraging their international networks to provide comprehensive services [7][8] - In the green finance sector, foreign banks are involved in innovative practices, such as ESG-linked loans and sustainable bond issuance, contributing to Shenzhen's green development initiatives [8] Group 4 - Shenzhen's favorable business environment, recognized as one of the best in the country, has attracted a significant number of foreign enterprises, with a 21.7% increase in newly established foreign companies in 2024 [9][10] - The city continues to enhance its policies to attract foreign investment, with new measures introduced to optimize the international business environment [9][10] - The ongoing development of foreign financial institutions in Shenzhen reflects China's commitment to high-level financial openness and a mutually beneficial financial development framework [10]